

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/jgo-22-643">https://dx.doi.org/10.21037/jgo-22-643</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	The study protocol, statistical analysis plan, and clinical study report will also be shared.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the survival data may be updated over time.
7	To whom will you share the data?	Medical oncologists who are interested in this study.
8	For what type of analysis or purpose?	For analysis to choose the effective second-line treatment in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib.
9	How or where can the data/documents be obtained?	Emails could be sent to this address: chen.yi1@zs-hospital.sh.cn; 13918876432@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.